RxDoctor Payments Data

Leslie Hayes

Neuromuscular Medicine · Boston, MANPI 1629422589

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,620 of the $10,539 with a category attached, or 81.8%. Novartis accounts for 86.4% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $9,250, more than ten times the $751 reported in 2022.

$10,539in general payments, 2019–2025

Across 16 payments — averaging $658.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$9K
  • PTC Therapeutics, Inc.$751
  • Biogen$302
  • Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$191
  • Genentech, Inc.$129
  • NS Pharma, Inc.$62
$451,006in research payments, 2019–2025

Across 13 payments — averaging $34,693 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$302K
  • Vertex$149K

What the payments were for

  • Consulting fees$8,62082%
  • Travel & lodging$9829%
  • Food & beverage$9069%
  • Education$310%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Massachusettsto place this figure against a meaningful peer group, so we don't.

Other neuromuscular medicine in Boston

Where these figures come from

Is this you, or does something look wrong? →